摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,5R)-2,5-dimethyl-1-(4-nitrophenyl)piperazine | 1030627-02-1

中文名称
——
中文别名
——
英文名称
(2S,5R)-2,5-dimethyl-1-(4-nitrophenyl)piperazine
英文别名
——
(2S,5R)-2,5-dimethyl-1-(4-nitrophenyl)piperazine化学式
CAS
1030627-02-1
化学式
C12H17N3O2
mdl
——
分子量
235.286
InChiKey
HZFREYKCBLRUCP-ZJUUUORDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    61.1
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    (2S,5R)-2,5-dimethyl-1-(4-nitrophenyl)piperazine乙酰氯 反应 16.0h, 生成 (2R,5S)-1-acetyl-2,5-dimethyl-4-(4-nitrophenyl)piperazine
    参考文献:
    名称:
    Chemical compounds
    摘要:
    本文描述了公式(I)的化合物,其中变量基团的定义如内部所述,并描述了药学上可接受的盐和体内可水解的酯。还描述了它们的制备过程以及它们作为药物的用途,特别是作为产生细胞周期抑制(抗细胞增殖)效果的药物,用于温血动物,如人类。
    公开号:
    US20070161615A1
  • 作为产物:
    描述:
    对氟硝基苯2,5-dimethyl-piperazine二氯甲烷 、 Brine 、 silica gel 、 methanol-dichloromethane 作用下, 以 乙腈 为溶剂, 反应 11.0h, 以Chromatography on silica gel with MeOH: DCM (1:99 to 5:95) gave the title compound as an oil which的产率得到(2S,5R)-2,5-dimethyl-1-(4-nitrophenyl)piperazine
    参考文献:
    名称:
    Chemical compounds
    摘要:
    本文描述了公式(I)的化合物,其中变量基团的定义如内部所述,并描述了药学上可接受的盐和体内可水解的酯。还描述了它们的制备过程以及它们作为药物的用途,特别是作为产生细胞周期抑制(抗细胞增殖)效果的药物,用于温血动物,如人类。
    公开号:
    US20070161615A1
点击查看最新优质反应信息

文献信息

  • [EN] IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION<br/>[FR] IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES UTILISES EN TANT QU'AGENTS INHIBITEURS DE LA PROLIFERATION CELLULAIRE
    申请人:ASTRAZENECA AB
    公开号:WO2005075461A1
    公开(公告)日:2005-08-18
    Compounds of the formula (I), wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti cell proliferation) effect in a warm blooded animal, such as man.
    化合物的公式(I),其中变量基团的定义如内部,并描述了药用盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途,特别是作为用于在温血动物(如人)中产生细胞周期抑制(抗细胞增殖)效果的药物。
  • Phenlypyridine carbonyl piperazine derivative
    申请人:——
    公开号:US20040192701A1
    公开(公告)日:2004-09-30
    The present invention relates to a compound which is represented by the following general formula and has type 4 phosphodiesterase inhibitory action, and uses and an intermediate compound thereof. 1 (wherein R1, R2: hydrogen, a halogen, a lower alkyl, a lower alkoxy, or the like, R3, R4: hydrogen, a (substituted) lower alkyl, a halogen, or the like, R5: hydrogen, a lower alkyd, a lower alkoxycarbonyl, or the like, and n: 0 or 1).
    本发明涉及一种化合物,其由以下通式表示,并具有4型磷酸二酯酶抑制作用,以及其中间体化合物和用途。(其中R1、R2:氢、卤素、低碳基、低烷氧基等,R3、R4:氢、(取代)低碳基、卤素等,R5:氢、低烷基、低烷氧羰基等,n:0或1)。
  • Chemical compounds
    申请人:Andrews Michael David
    公开号:US20070161615A1
    公开(公告)日:2007-07-12
    Compounds of the formula (I), wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti cell proliferation) effect in a warm blooded animal, such as man.
    本文描述了公式(I)的化合物,其中变量基团的定义如内部所述,并描述了药学上可接受的盐和体内可水解的酯。还描述了它们的制备过程以及它们作为药物的用途,特别是作为产生细胞周期抑制(抗细胞增殖)效果的药物,用于温血动物,如人类。
  • Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
    申请人:Edwards Paul John
    公开号:US20090105242A1
    公开(公告)日:2009-04-23
    Novel triazolopyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.
    本发明公开了一种具有以下式子表示的新型三唑基吡啶化合物:这些化合物可以制备为药物组合物,并可用于预防和治疗哺乳动物,包括人类的各种疾病,例如ECM降解,关节降解和/或炎症等。
  • Phenylpyridinecarbonylpiperazinederivative
    申请人:Astellas Pharma Inc.
    公开号:US07196080B2
    公开(公告)日:2007-03-27
    The present invention relates to a compound which is represented by the following general formula and has type 4 phosphodiesterase inhibitory action, and uses and an intermediate compound thereof. (wherein R1, R2: hydrogen, a halogen, a lower alkyl, a lower alkoxy, or the like, R3, R4: hydrogen, a (substituted) lower alkyl, a halogen, or the like, R5: hydrogen, a lower alkyl, a lower alkoxycarbonyl, or the like, and n: 0 or 1).
    本发明涉及一种化合物,该化合物由以下通式表示,并具有4型磷酸二酯酶抑制作用,以及其中间体化合物和用途。(其中R1、R2:氢、卤素、较低的烷基、较低的烷氧基或类似物,R3、R4:氢、(取代的)较低的烷基、卤素或类似物,R5:氢、较低的烷基、较低的烷氧羰基或类似物,n:0或1)。
查看更多